Your session is about to expire
← Back to Search
Berzosertib + Standard Chemotherapy for Lung Cancer
Study Summary
This trial is testing a combination of drugs to treat squamous cell non-small cell lung cancer. The drugs are given to see if they work better than just the chemotherapy drugs carboplatin and gemcitabine.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have no allergies to berzosertib, pembrolizumab, gemcitabine, carboplatin, or similar drugs.I do not have any ongoing infections or recent vaccinations.I should be cautious with Berzosertib due to my genetic condition affecting DNA repair.I can provide tumor tissue samples or am willing to have a biopsy for study purposes.I had platinum-based chemotherapy for early-stage lung cancer over a year ago and haven't had chemo or immunotherapy for metastatic disease.My lung cancer is mainly squamous cell type and is stage IV.I completed immunotherapy for early-stage cancer over a year ago.I do not have severe bone marrow issues or major bleeding.I haven't taken strong immune-weakening medicines in the last 28 days, except for low-dose steroids or inhalers.My brain metastases are stable, and I'm on a steady dose of medication for it.I haven't had radiation therapy within a week before taking gemcitabine.I am not taking strong medication that affects how my body processes certain drugs.I can understand and am willing to sign the consent form, or I have someone who can do it for me.My heart function is classified as class 2B or better, despite my history of heart issues or treatments.Your platelet count is higher than the lower limit of normal.I have another cancer type, but it won't affect this trial's treatment.Patients must have a specific amount of disease that can be measured using a standard method.I am 18 years old or older.Your AST and ALT levels in your blood are not more than three times the normal limit at the hospital where you are being treated.I have not had a solid organ transplant or needed immunosuppressants for autoimmune disease in the last 2 years.I am fully active or can carry out light work.I have not had chemotherapy for cancer that has spread.Your bilirubin levels are within the normal range set by the hospital.I have chronic hepatitis B but it's under control with treatment.Your white blood cell count is too low.I am not pregnant or breastfeeding.Your white blood cell count is at least 3,000 per microliter.My kidney function is within the safe range for the trial.I have not had a stem cell transplant from another person.I have HIV, am on effective treatment, and my viral load is undetectable.I had hepatitis C but am cured, or I'm being treated with no detectable virus.
- Group 1: Arm A (pembrolizumab, gemcitabine, carboplatin, M6620)
- Group 2: Arm B (pembrolizumab, gemcitabine, carboplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this study being conducted in several hospitals around town?
"There are 16 recruiting patients for this clinical trial such as University of Pittsburgh Cancer Institute (UPCI) in Pittsburgh, Siteman Cancer Center at West County Hospital in Creve Coeur, and Dartmouth Hitchcock Medical Center in Lebanon."
Why did researchers design this trial in this way?
"The primary outcome of this trial, which will be measured over a From the date of randomization to time of progression or death, whichever occurs first, assessed up to 12 months post treatment time frame is to Recommended phase 2 dose (RP2D) (Phase 1B). Secondary outcomes include Worst grade of adverse events which is defined as Adverse events will be tabulated according to Common Terminology Criteria for Adverse Events version 5.0 type, grade and relation to treatment. The worst grade of adverse event will be determined for each participant, and the distributions of worst grades will be compared between arms using a cumulative logit model."
Is this the first time Pembrolizumab has been trialed?
"Pembrolizumab is being trialed in 409 Phase 3 clinical studies with a total of 1964 active trials. 84434 locations are running these tests, with the majority located in Shanghai, China."
Are patients being accepted into this research project at this time?
"This clinical trial is still recruiting patients, according to the latest information on clinicaltrials.gov. The trial was originally posted on June 1st, 2020 and was last updated on November 15th, 2022."
What are some conditions that Pembrolizumab has been found to be an effective treatment for?
"Pembrolizumab is an effective treatment for various types of cancer, including lymphoma, non-Hodgkin's melanoma, and recurrent cervical cancer."
Share this study with friends
Copy Link
Messenger